On the contrary, in the United States, it was found that 15% of medical trainees had initiated anemia treatment at Hb levels <11 g/dL.[46] These observations reflect a less-than-optimal screening/monitoring/management of patients with CKD in China. The gene discussed is GSTM1; the disease is chronic kidney disease.